Full Breakdown
Minty Boost: How GLP-1 Weight-Loss Drugs Are Driving Hershey’s Gum Sales
5/2/2026, 2:56:52 AM
The Core Event: Ice Breakers Sales Surge Amid “Ozempic Breath”
Hershey reported an 8 % rise in retail sales of its Ice Breakers gum and mint line in the first quarter of 2026. The company linked the increase to “functional snacking tailwinds” created by the growing use of GLP-1 weight-loss drugs, which many users experience as bad breath—informally called “Ozempic breath.”
GLP-1 Drugs and Oral Side Effects
GLP-1 receptor agonists such as Ozempic, Wegovy and Mounjaro suppress appetite by slowing gastric emptying. Medical professionals note that the resulting dry mouth, reduced saliva flow, and occasional ketosis foster bacterial growth that produces foul-smelling volatile sulfur compounds. Dr. Neha Lalani described the condition as “a fishy smell in burps or bad breath.” Ann Marie Defnet of Northwell Health emphasizes the need for patients to stay hydrated, while Lancaster University professor Adam Taylor explained that the drugs “reduce the flow of saliva… encouraging bacteria that contribute to bad breath and the formation of cavities to thrive.”
Data & Statistics
- Ice Breakers sales: +8 % YoY.
- Hershey protein-bar sales: +17 % YoY.
- Quarterly revenue: $3.10 billion vs. $3.03 billion estimate.
- North-American salty-snack volume: +5 %; confection volume: -4 %.
- Households with at least one GLP-1 user cut grocery spending by 5.3 % in the first six months.
- Novo Nordisk trial: 9 % of participants reported eructation; 40 % nausea; 25 % vomiting.
- Industry analysts project 30 million GLP-1 users in the United States by 2030.
Official Statements & Responses
Hershey CEO Kirk Tanner said the company is “seeing strong demand for gum and mint products as the category benefits from functional snacking tailwinds, including GLP-1 adoption.” He added that “functional snacking is a small but mighty part of our growth and you’ll see the investment in innovation.” Swiss chocolatier Lindt & Spruengli and The Magnum Ice Cream Company similarly noted a “premium treat substitution effect” as GLP-1 users shift toward smaller-portion, higher-protein products. Medical experts caution that halitosis is not listed as an official side effect of GLP-1 drugs and that the phenomenon remains under clinical study.
Criticism & Opposition
GLP-1 manufacturers do not include bad breath on product labels. Physicians argue that “Ozempic breath” is not a clinical diagnosis and that the oral-health implications are still being researched. Analysts such as AlixPartners warn that the gum-sales boost may be temporary, noting that many GLP-1 users discontinue therapy within a year, after which traditional snacking patterns often resume.
Conflicting Reports & Gaps
No consensus exists on the prevalence of halitosis among GLP-1 users; Novo Nordisk’s trial reports eructation but not direct measurements of bad breath. The lack of standardized terminology and diagnostic criteria for “Ozempic breath” creates uncertainty about the true market size for oral-care products linked to these drugs.
Why It Matters: Shifting Snack Landscape
The rise of “functional snacking” illustrates a broader shift from calorie-dense indulgences to products that address specific health-related needs. As consumers prioritize oral freshness and hydration, premium chocolate, ice cream and protein snacks are gaining share, while traditional candy volumes decline. This realignment is reshaping growth strategies for major food companies.
What’s Next
Industry observers expect continued expansion of “GLP-1-friendly” labeling and targeted marketing of gum, mints and other oral-care items. Monitoring of GLP-1 adoption rates and user discontinuation will determine whether the current gum boom sustains beyond 2026.
Verbatim Quotes
- “Retails sales for our third-largest confection brand, Ice Breakers, increased over 8% in the quarter.” — Kirk Tanner, CEO, Hershey
- “Ozempic breath refers to a fishy smell in burps or bad breath,” — Dr. Neha Lalani, Healthline
- “Drinking water regularly during the day can help to keep the oral surfaces from drying out,” — Adam Taylor, Lancaster University
- “We are seeing a significant functional snacking tailwind,” — Kirk Tanner, Hershey CEO
- “The adoption of GLP-1 medications is creating a new type of consumer—one who prioritizes oral freshness and hydration over traditional indulgence.” — Kirk Tanner, Hershey CEO
- “It (functional snacking) is a small but mighty part of our growth and you'll see the investment in innovation,” — Kirk Tanner, Hershey CEO
